{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:19:06Z","timestamp":1773026346993,"version":"3.50.1"},"reference-count":29,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Fibroblast activation protein inhibitor (FAPI) PET was initially developed for cancer diagnostics; however, studies suggest that FAPI PET is a promising modality in various fibrotic diseases, including interstitial lung disease, fibrotic myocardial diseases, and rheumatic diseases such as rheumatoid arthritis, IgG4-related disease, and systemic scleroderma. There are limited studies on the subject, but this review finds that FAPI PET can accurately and specifically visualise active fibrosis and holds potential for monitoring treatment response and differentiation between inflammation and fibrosis.<\/jats:p>","DOI":"10.61409\/v04250306","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:04:42Z","timestamp":1763553882000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast activation protein inhibitor PET for monitoring fibrotic diseases"],"prefix":"10.61409","author":[{"given":"Rikke Helin","family":"Johnsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja Bjerregaard","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saher B.","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoffer Tandrup","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Plikus MV, Wang X, Sinha S et al. Fibroblasts: origins, definitions, and functions in health and disease. Cell. 2021;184(15):3852-3872. https:\/\/doi.org\/10.1016\/j.cell.2021.06.024","DOI":"10.1016\/j.cell.2021.06.024"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3","DOI":"10.1007\/s10555-020-09909-3"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bentestuen M, Al-Obaydi N, Zacho HD. FAPI-avid nonmalignant PET\/CT findings: an expedited systematic review. Semin Nucl Med. 2023;53(5):694-705. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.02.001","DOI":"10.1053\/j.semnuclmed.2023.02.001"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Mori Y, Haberkorn U, Giesel FL. 68Ga- or 18F-FAPI PET\/CT-what it can and cannot. Eur Radiol. 2023;33(11):7877-7878. https:\/\/doi.org\/10.1007\/s00330-023-09715-9","DOI":"10.1007\/s00330-023-09715-9"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mori Y, Novruzov E, Schmitt D et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). Npj Imaging. 2024;2(1):48. https:\/\/doi.org\/10.1038\/s44303-024-00053-z","DOI":"10.1038\/s44303-024-00053-z"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(13):4377-4385. https:\/\/doi.org\/10.1007\/s00259-021-05307-1","DOI":"10.1007\/s00259-021-05307-1"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Meyer C, Dahlbom M, Lindner T et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61(8):1171-1177. https:\/\/doi.org\/10.2967\/jnumed.119.236786","DOI":"10.2967\/jnumed.119.236786"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Yang P, Luo Q, Wang X et al. Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases. Am J Respir Crit Care Med. 2023;207(2):160-172. https:\/\/doi.org\/10.1164\/rccm.202110-2414OC","DOI":"10.1164\/rccm.202110-2414OC"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"R\u00f6hrich M, Leitz D, Glatting FM et al. Fibroblast activation protein-specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J Nucl Med. 2022;63(1):127-133. https:\/\/doi.org\/10.2967\/jnumed.121.261925","DOI":"10.2967\/jnumed.121.261925"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mori Y, Kramer V, Novruzov E et al. Initial results with [18F]FAPI-74 PET\/CT in idiopathic pulmonary fibrosis. Eur J Nucl Med Mol Imaging. 2024;51(6):1605-1611. https:\/\/doi.org\/10.1007\/s00259-023-06564-y","DOI":"10.1007\/s00259-023-06564-y"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hotta M, Kim GHJ, Rerkpichaisuth V et al. Correlation of FAPI PET uptake with immunohistochemistry in explanted lungs from patients with advanced interstitial lung disease. J Nucl Med. 2024;65(11):1789-1794. https:\/\/doi.org\/10.2967\/jnumed.124.268351","DOI":"10.2967\/jnumed.124.268351"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Bergmann C, Distler JHW, Treutlein C et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2021;3(3):e185-e194. https:\/\/doi.org\/10.1016\/S2665-9913(20)30421-5","DOI":"10.1016\/S2665-9913(20)30421-5"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Kastrati K, Nakuz TS, Kulterer OC et al. FAPi PET\/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study. EClinicalMedicine. 2024;72:102598. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102598","DOI":"10.1016\/j.eclinm.2024.102598"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Rajiah PS, Fran\u00e7ois CJ, Leiner T. Cardiac MRI: state of the art. Radiology. 2023;307(3):223008. https:\/\/doi.org\/10.1148\/radiol.223008","DOI":"10.1148\/radiol.223008"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Diekmann J, Koenig T, Thackeray JT et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with MR tissue characterization and subsequent functional outcome. J Nucl Med. 2022;63(9):1415-1423. https:\/\/doi.org\/10.2967\/jnumed.121.263555","DOI":"10.2967\/jnumed.121.263555"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Zhang M, Quan W, Zhu T et al. [68Ga]Ga-DOTA-FAPI-04 PET\/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling. Eur J Nucl Med Mol Imaging. 2023;50(3):839-848. https:\/\/doi.org\/10.1007\/s00259-022-06015-0","DOI":"10.1007\/s00259-022-06015-0"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Loganath K, Craig N, Barton A et al. Cardiovascular PET imaging of fibroblast activation: a review of the current literature. J Nucl Cardiol. 2025;47:102106. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102106","DOI":"10.1016\/j.nuclcard.2024.102106"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Barton AK, Craig NJ, Loganath K et al. Myocardial fibroblast activation after acute myocardial infarction: a positron emission tomography and magnetic resonance study. J Am Coll Cardiol. 2025;85(6):578-591. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.103","DOI":"10.1016\/j.jacc.2024.10.103"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Wang L, Wang Y, Wang J et al. Myocardial activity at 18F-FAPI PET\/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy. Radiology. 2023;306(2):221052. https:\/\/doi.org\/10.1148\/radiol.221052","DOI":"10.1148\/radiol.221052"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Wang X, Shen K, Zhang Y et al. Molecular stratification of light-chain cardiac amyloidosis with 18F-florbetapir and 68Ga-FAPI-04 for enhanced prognostic precision. JACC Cardiovasc Imaging. 2025;18(3):323-336. https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.001","DOI":"10.1016\/j.jcmg.2024.10.001"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Singh SB, Bhandari S, Bhandari S et al. Role of PET\/CT in diagnosing and monitoring disease activity in rheumatoid arthritis: a review. Ann Nucl Med. 2024;38(3):165-175. https:\/\/doi.org\/10.1007\/s12149-023-01896-z","DOI":"10.1007\/s12149-023-01896-z"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Luo Y, Pan Q, Zhou Z et al. 68Ga-FAPI PET\/CT for rheumatoid arthritis: a prospective study. Radiology. 2023;307(3):222052. https:\/\/doi.org\/10.1148\/radiol.222052","DOI":"10.1148\/radiol.222052"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Pan Q, Yang H, Zhou Z et al. [68Ga]Ga-FAPI-04 PET\/CT may be a predictor for early treatment response in rheumatoid arthritis. EJNMMI Res. 2024;14(1):2. https:\/\/doi.org\/10.1186\/s13550-023-01064-4","DOI":"10.1186\/s13550-023-01064-4"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Bucci L, Hagen M, Rothe T et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30(5):1593-601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1","DOI":"10.1038\/s41591-024-02964-1"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Wallace ZS, Zhang Y, Perugino CA et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78(3):406-412. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214603","DOI":"10.1136\/annrheumdis-2018-214603"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Schmidkonz C, Rauber S, Atzinger A et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79(11):1485-1491. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217408","DOI":"10.1136\/annrheumdis-2020-217408"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Treutlein C, Distler JHW, Tascilar K et al. Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04 PET\/CT. Eur J Nucl Med Mol Imaging. 2023;50(6):1629-1635. https:\/\/doi.org\/10.1007\/s00259-022-06081-4","DOI":"10.1007\/s00259-022-06081-4"},{"key":"ref27","unstructured":"Clinical Trials Easily Understood. Study on [68Ga]Ga-FAPI-46 PET\/CT imaging for better diagnosis in patients with pancreatic and gastroesophageal cancer, Trial ID: 2023-503632-41-00, 2025 (10. sep 2025)"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Bentestuen M, Ladekarl M, Knudsen A, Zacho HD. Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET\/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial. BMC Cancer. 2024;24(1):699. https:\/\/doi.org\/10.1186\/s12885-024-12461-w","DOI":"10.1186\/s12885-024-12461-w"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:32:22Z","timestamp":1763641942000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V04250306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":29,"URL":"https:\/\/doi.org\/10.61409\/v04250306","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}